Health
globalreutersOctober 11, 20241 Mins read
Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M
globalreutersOctober 11, 20241 Mins read 
Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and Ceribell also priced IPOs to join the public markets.
The post Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Heat-related illnesses are preventable; here’s how
By PHIYEN NGUYEN & KRISTINA CARVALHO As we enjoy the crisp air...
WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs
Employers are prioritizing mental wellbeing programs, but employees say they need financial...
Best hospital for Congenital Hip Dislocation Treatment
Developmental dysplasia of the hip, also known as congenital hip dislocation, is...
A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria
That is the title of my recent paper with co-authors Denise Clayton,...
Leave a comment